Anavex Life SciencesAVXL.OValuation Analysis

As of Oct 16, 2026, Anavex Life Sciences (AVXL.O) trades at a negative P/E (-9.33x, due to a recent net loss), P/B of 1.08x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 24th percentile within its industry and the 32nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Anavex Life Sciences operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.